Cell and Gene Therapies – The Next Transformative Pillar of Medicine
Genes. Chromosomes. Mutations. Today, these terms are as likely to be overheard in a casual dinner conversation as they are in scientific symposia and medical congresses. While the discovery of DNA dates back to 1869 when Swiss biochemist Johann Friedrich Miescher discovered nucleic acid, it was not until James Watson and Francis Crick published in...
Read moreUshering in a new era for cancer therapy
Almost 40% of people will be diagnosed with cancer during their lifetime. In 2020, cancer accounted for about 10 million deaths globally. That means almost one in six deaths was due to cancer. For many of us, cancer is very close. It could be a loved one or even ourselves. The impact of cancer is...
Read more
IFPMA calls for regulatory convergence to speed up development of much needed vaccines
GENEVA, 2 September 2019 – Today, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) launched a new report titled ‘Complex Journey of a Vaccine: The Steps behind Developing a New Vaccine’. The report highlights three major factors that contribute to the lengthy development process of a novel vaccine, and highlights the challenges that manufacturers...
Read moreGlobal Pharma update on unprecedented efforts to collaborate in speeding up the search for safe and effective COVID-19 therapies
Geneva, April 30, 2020: R&D biopharmaceutical companies have brought together their best people, resources and expertise to accelerate the development of new treatments for use in the fight against COVID-19. The R&D biopharmaceutical companies are working with urgency to research and test potential COVID-19 treatments, without compromising safety and quality. To ensure that nobody is...
Read moreJoint statement on World Antimicrobial Awareness Week
To mark World Antimicrobial Awareness Week (WAAW) 2023, the International Alliance of Patients’ Organizations (IAPO), the IAPO Patients for Patient Safety Observatory and its AMR Patient Alliance, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the World Medical Association (WMA), the International Council of Nurses (ICN) and International Pharmaceutical Federation (FIP), call for cross-sectoral collaboration to address the growing threat of AMR.
Read moreWHA 65 agenda item 13.14 on consultative expert working group on research and development
IFPMA Statement, WHA 65, Item 13.14, Consultative expert working group on research and development: financing and coordination Delivered by Mario Ottiglio, Associate Director, Public Affairs & Global Health Policy Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), for the opportunity to provide our perspective on this topic. We represent...
Read moreForging New Approaches to Biopharmaceutical Innovation in Neuroscience
As a psychiatrist, I have long worked to address mental diseases such as schizophrenia and depression. Experiencing first-hand the suffering and heavy burden these ailments place on people motivated me early on in my career to better understand the underlying mechanisms of these diseases and to help find new treatment possibilities. This is why I...
Read moreWhat you need to know about dementia so that you don’t forget
September is World Alzheimer’s Month, an international campaign to challenge the stigma that surrounds dementia, a disease that affects almost 150,000 people in Switzerland. It is the third most frequent cause of death in the country, costing over CHF 7 billion a year – and as many as 400,000 predominantly elderly Swiss people may live...
Read moreThe global biopharmaceutical industry’s united front against COVID-19
In recent weeks, we have seen an unprecedented rapid response from governments, international organisations, health care professionals, the biopharmaceutical industry and many others to respond to one of the biggest global health crisis the world has experienced in recent decades: the novel coronavirus, or so-called COVID-19. Both professionally but also personally I think it’s remarkable...
Read moreWhat will it take to produce the billions of vaccines needed against COVID-19?
Published on Thomas Cueni’s LinkedIn profile. COVID-19 is not business as usual for any of us, especially not for the pharmaceutical industry. As we enter into the sixth month of the COVID-19 pandemic, I think it is no understatement to say that the global biopharmaceutical industry has been at the forefront of efforts from day...
Read more